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A genetic variation in fatty acid amide hydrolase
(FAAH), C385A (P129T), has been previously
associated with risk for problem street drug use.
FAAH is a mammalian enzyme that inactivates
neuromodulatory-signaling lipids including the
endogenous cannabinoid 1 receptor agonist ana-
ndamide. We investigated in adult Caucasians
(N¼749) whether this FAAH variant altered the
risk for trying, regular use of or dependence on
cannabis, alcohol or nicotine, traditional ‘‘gate-
way’’ drugs. Consistent with our knowledge that
the A/A genotype results in reduced FAAH expres-
sion and activity in humans, subjects with the A/A
genotype were less likely to be THC dependent
than subjects with either a C/C or C/A genotype
(11% vs. 26%, P<0.05). No association was
observed between the A/A genotype and risk for
alcohol or tobacco regular use, or DSM IV depen-
dence. Controlling for regular use of nicotine and
sedatives, both identified as confounders, those
with the A/A genotype were at significantly
reduced risk for being THC dependent (OR 0.25,
95% CI: 0.07–0.88) as compared with those with the
C/A or C/C genotype, supporting a link between
alterations in the endocannabinoid system and
THC dependence. Unexpectedly, we found an
increased risk for regular use of sedatives among
the A/A genotype group. The relationship between
the FAAH A/A genotype and risk for drug depen-
dence in this study was drug class specific,
suggesting it is not part of a more general
drug abuse effect. These results, particularly the
observation of altered risk for sedative drug use,
should be investigated further in multiple ethnic
populations.  2007 Wiley-Liss, Inc.
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INTRODUCTION
Fatty acid amide hydrolase (FAAH) is amammalian enzyme
in the nervous system and periphery that inactivates a variety
of compounds in the fatty acid amide family of neuromodula-
tory signaling lipids, including the endogenous cannabinoid,
anandamide (AEA), and the sleep-inducing lipid, oleamide
(OEA) [Deutsch et al., 2002; McKinney and Cravatt, 2005].
Several of the naturally occurring amidated fatty acid
endocannabinoid compounds are agonist-type ligands for the
cannabinoid receptor, type 1 (CB1) [Howlett, 2002; Howlett
et al., 2002]. The CB1 receptor is densely expressed in
numerous brain regions, particularly in the mesolimbic
dopamine addiction/reward pathway in the ventral striatum
where it has been co-localized with FAAH in a complementary
pattern of expression [Egertova et al., 2003]. Recent studies in
humans have identified the naturally occurring FAAH C385A
(P129T) variant and have demonstrated an increased inci-
dence of the homozygous FAAH cDNA þ385 A/A genetic
variant in subjects with problem drug use, primarily with
street drugs of abuse [Sipe et al., 2002]. Biochemical and cell
biological studies of this FAAH variant have shown that the
P129T variant FAAH protein has reduced expression and
activity in humans supporting a link between defects in the
endocannabinoid system and drug use [Chiang et al., 2004].
There is growing evidence from animalmodels that alterations
in the endogenous cannabinoid system contribute to tolerance
and dependence in several classes of abused substances but
data fromhuman studies on specific drugs of abuse are limited.
The contribution to abuse liability may be general, perhaps
directly via alterations in anxiety or emotional states, or itmay
be specific to particular drugs. However, the specific drug, or
drugs of abuse, for which the FAAH C385A genetic variation
may confer selective vulnerability remains unknown.
To begin investigations in this area we elected to focus on
three specific drugs, each frequently tried during early
experimentation with drug use and each associated with
genetic influences of risk of dependence and/or regular use
[Wilhelmsen and Ehlers, 2005]. The first was cannabis sativa
(with its main psychoactive component D-9-tetrahydrocanna-
binol, THC) whichwas selected as a drug specifically related to
the cannabinoid signaling system of the CNS, under study
[Tanda et al., 1997; De Vries and Schoffelmeer, 2005]. The
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relationship between THC abuse and the FAAH þ385 variant
might be predicted from the previous association study with
street drug use [Sipe et al., 2002]. Based on the previous
observation of the FAAH genotype associated with an
increased risk of street drug use, we hypothesized that the
FAAHA/A genotypewould be associatedwith a greater risk for
DSM IV dependence on THC. However, neither previous
studies have examined drug dependence, relative to drug use,
nor the influence of the FAAH genotype on specific drug
dependences such as THC dependence.
Along with THC [Hall and Lynskey, 2005], the second and
third drugs of interest, nicotine and alcohol, are often
considered gateway drugs however their ‘‘use’’ was not
associated with the FAAH þ385 A/A genetic variant in a
previous study [Sipe et al., 2002]. Here, we re-assessed these
two drugs in terms of risk for DSM IV dependency because the
risk for alcohol and nicotine dependence, versus use, may have
a larger genetic contribution [Tyndale, 2003]. In the case of
nicotine, it has been shown that mice lacking CB1 receptors do
not show nicotine place preference [Castane et al., 2002, 2005]
and CB1 antagonists block the motivational and dopamine-
releasing properties of nicotine in rats [Cohen et al., 2002].
Moreover, the CB1 antagonist, rimonabant, is currently being
developed to treat nicotine dependence [Fernandez and
Allison, 2004; Foulds et al., 2004], indicating the significance
of the endocannabinoid system’s role in aspects of nicotine
craving and dependence.
Current evidence also suggests that the endocannabinoid
system may mediate alcohol intake and the motivational
properties of alcohol [Gessa et al., 2005; Gonzalez et al., 2005].
For example, mice lacking the CB1 receptor show reduced
conditioned place preference for alcohol [Houchi et al., 2005]
while in rats THC can reinstate alcohol-seeking behavior
[McGregor et al., 2005]. Neuroadaptation to chronic ethanol
has been shown to involve changes in the endocannabinoid
system [Vinod and Hungund, 2005]. Taken together, these
findings provide additional reasons for further examination of
the role of the FAAH genetic variation in alcohol dependence.
Our primary goal in this study was to investigate the
association of the FAAHþ385A/A (P129T) genetic variation in
a subject population with known use of THC (tried vs. not
tried). Among those who had tried THC we also investigated
the risk for THC DSM IV dependence. Additionally, the
relationship of the FAAH þ385 A/A genotype to the regular
use of other commonly abused drugs by THC users was
investigated. This was done in order to explore whether the
FAAH genotype was associated only with specific drug classes,
or whether it is part of a more general drug use phenomenon.
We also extended the previous investigation of nicotine and
alcohol use [Sipe et al., 2002] by determining the association of
the FAAHþ385 A/A genotype group with DSM IV dependence
on alcohol and nicotine, among those who had already tried
them [Schoedel et al., 2004]. For all three drugs we have
examined the risk for use, regular use, and DSM IV
dependence since it has been shown that the endophenotype
used in genetic association studies can influence the outcomes
[Schoedel et al., 2004]. While our principal hypotheses focused
on DSM IV dependence, providing data on each of these
phenotypes allows for better comparisons with other studies.
MATERIALS AND METHODS
FAAH Gene Sequencing and SNP Genotyping
PCR conditions and oligonucleotide primer methods were
based on sequencing the 15 coding exons in theFAAHgene and
over 1,500 coding exons in our previous study on the human
FAAH gene [Sipe et al., 2002]. The FAAH cDNA þ385 C!A
single nucleotide polymorphism (SNP) was identified as
significant because it predicts substitution of the highly
conserved amino acid residue Proline 129 to Threonine
(P129T). The P129T variant enzyme protein exhibits reduced
cellular stability with decreased hydrolyzing function and
expression in humans due to a post-translational mechanism
that precedes productive folding of the FAAH protein [Chiang
et al., 2004]. Therefore, this variant was selected for high
throughput genotype screening by allele-specific oligonucleo-
tide hybridization (ASOH) [Beutler and Gelbart, 2000].
Briefly, the ASOH method was used to determine the FAAH
cDNA þ385 nucleotide genotypes of all anonymous subjects
whereDNA sampleswere available in this study. Radiolabeled
oligonucleotide ASOH primers, conditions and digital imaging
techniques using theCyclone PhosphoImager1were identical
to those recently described [Sipe et al., 2002].
Research Subjects and Study Measures
The entire population was a community-based sample of
2,078 unrelated healthy volunteers who were recruited using
newspaper and flyer advertisements in Toronto, Ontario,
Canada as previously described [Schoedel et al., 2004]. In an
effort to minimize population stratification and admixing, the
study sample for these analyses was restricted to a total of 749
subjects who self-reported either three or four of their grand-
parents as Caucasian.
Demographic information, including sex, ethnicity, and
education, as well as drug use and dependence were collected
by structured interview and questionnaire as previously
described [Tyndale et al., 1997; Schoedel et al., 2004]. Drug
use was measured as ‘‘tried’’ (‘‘Have you ever used?’’), regular,
and dependent (DSM-IV criteria). Regular use was defined as
follows with the lifetime as the reference period: alcohol
(had more than 1 drink/month for 3 consecutive months);
anti-depressants, sedatives, and stimulants (used at least 2–
3 times/month for 3 consecutive months); hallucinogens (used
10 or more times); nicotine (smoked 100 or more cigarettes);
opiates (used opiates at least 2–3 times/month for 3 con-
secutive months or used heroin 10 or more times); and THC
(smoked 10 or more joints).
The procedures relating to the recruitment and genotyping
of the subjects were approved and monitored by the Sunny-
brook andWomen’s CollegeHealth SciencesCentre’s Research
Ethics Board and the Scripps Institutional Review Board. All
subjects provided informed, written consent in accordance
with the approved protocols.
Statistical Methods
Analyses pertaining to the relationship between FAAH
genotype and having tried THC were conducted within the
study sample as awhole (N¼ 749). Analyses of the relationship
between FAAH genotype and THC regular use or dependence
were conducted within the group of subjects who reported
having tried THC (N¼ 489, Fig. 1).
Comparisons of proportions were carried out using
Chi-Square tests (SAS), and where cell sizes were equal to or
smaller than 5, the Fisher’s exact test (EastStat, one-side) was
used. For additional analyses beyond those hypothesized, the
analyses were hypothesis-generating, rather than hypothesis-
testing, and therefore no specificmethod of correctionwasused
to adjust for multiple testing (e.g., Bonferroni adjustment) but
rather are included to enable the reader to draw their own
conclusions. Logistic regressionmodels were used tomodel the
relationship between FAAH genotype and THC. Odds ratios,
and associated 95% confidence intervals, were calculated for
FAAH alone, as well as controlling for other classes of regular
drug use. A change of approximately 10% in the odds ratio was
used to identify confounders of the relationship betweenFAAH
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genotype and THC. The same approaches were used to
independently assess the association of nicotine, alcohol, and
sedative use. Given the nature of the subject recruitment and
the size of the study sample, these analyses should be
considered to be exploratory and hypothesis-generating in
nature, therefore, larger effect sizes can be considered
suggestive of an association and more interpretative ‘‘weight’’
should be placed on the effect sizes (e.g., odds ratios), than on
the P-values.
RESULTS
Demographics of Study Population
The study sample (Fig. 1) consisted of 749 Caucasians for
whom there were FAAH genotype data available; 489 of these
subjects had reported trying THC. In the study sample
there were no statistically significant differences in comparing
the FAAH þ385 C/A and C/C genotype group against the A/A
group genotype in terms of age (mean 41.6 vs. 40.7 years,
P¼ 0.73), gender (49.6% female vs. 45.7%, P¼ 0.65), nor level
of educational (partitioned into 3 or 6 groups, from not
completing high school to Ph.D. /M.D. degree, P> 0.05).
Similarly, there were also no statistically significant differ-
ences byFAAHgenotypewithin the subgroup of thosewho had
triedTHC:meanage36.6 vs. 36.2 years,P¼ 0.89; 50.3% female
vs. 51.8%, P¼ 0.88; and education (P> 0.05).
We hypothesized that the A/A genotype group would be at
altered risk for THC use, relative to the C/A and C/C groups,
based on the previous literature [Sipe et al., 2002], however we
initially examined the risk for trying THC and THC depen-
dence (as extreme phenotypes) for each of the three genotypes
separately. Among the whole study population (N¼ 749),
77.1% of A/A group (N¼ 27 of 35) had tried THC in contrast
to 61.1% (N¼ 132 of 216) and 66.3% (N¼ 330 of 498) of the C/A
andCCgroups, respectively. Amongall study subjectswhohad
tried THC (N¼ 489), 11.1% (N¼ 3 of 27) of the A/A genotype
group was THC dependent. In contrast, 23.5% (N¼ 31 of 132)
and 28.2% (N¼ 93 of 330)were THCdependent for the C/A and
C/C genotype groups, respectively. For both phenotype
associations, THC tried and THC dependent, the A/A group
was the distinct groupwhile theC/A andC/C groupswere quite
similar, consistentwith theprevious genotype groupings in the
literature (Houchi et al., 2005). We also examined the risk for
trying THCandTHC regular use and dependence inA/AþC/A
compared to the C/C individuals and did not observe any
associations supporting the finding that two copies of the
FAAH þ385 A allele are required [Chiang et al., 2004]. Thus
the A/A genotype was compared to the C/A and C/C genotypes
for the subsequent analyses.
THC Drug Use Stratified by FAAH Genotype
In Table I the frequencies of FAAH þ385 genotypes are
shown separately for the full study sample (Table IA) and for
the subgroup of those who tried THC (Table IB). The results in
Table IA suggest that subjects with the FAAH þ385 A/A
genotype showed an non-significant trend towards being more
likely to have tried THC than those with the C/A or C/C
genotypes (77.1% vs. 64.7%, P¼ 0.18). Among those who tried
THC, regular use of THC showed a non-significant trend
towards being lower for the A/A genotype compared to the C/A
or C/C genotype (55.6% vs. 61.2%, P¼ 0.56). However, as
criteria for the drug use phenotype became more stringent, in
this case using DSM-IV dependence, those with the A/A
genotype were significantly less likely to be THC dependent
than those with the C/A and C/C genotypes (11.1% vs. 26.8%,
P¼ 0.049) among those having tried THC (Table IB).
We also examined regular use of other drugs between the
genotype groups. In the total sample (Table IA), subjects with
the FAAH þ385 A/A genotype were no more likely to report
regular use of alcohol (85.7% vs. 83.6%, P¼ 0.48), however,
they were slightly more likely (not significant) to report
regular use of nicotine (71.4% vs. 60.9%, P¼ 0.21). Subjects
with the FAAH þ385 A/A genotype were significantly
more likely to report regular use of sedatives (31.4% vs.
14.7%,P¼ 0.008). In terms of regular drug use among the total
group (Table IA), there was little difference between the two
FAAHþ385 genotype groups in the reported use of anumber of
other drugs of abuse such as hallucinogens, opiates or
stimulants.
Similarly, within the subgroup of those who tried THC
(Table IB), FAAH þ385 A/A genotype subjects were modestly
(not significant) more likely to report regular use of nicotine
(88.9% vs. 77.3%, P¼ 0.12) however, they were significantly
more likely to report regular use of sedatives (37.0% vs. 16.9%,
P¼ 0.008). There was no difference by genotype in the regular
use of alcohol or the remaining drugs of abuse (Table IB).Given
these apparent drug specific effects of the FAAH genotype,
further analyses were conducted in an effort to determine
whether these effect sizes were related to only specific drug
classes or whether this was part of an overall general drug
effect. However, there was no difference by genotype in the
number of drugs used regularly. This suggested that the effect
was restricted to specific drugs (Table III) andwas not part of a
general drug effect.
Fig. 1. Study sample and subgroups by THC use and dependence.
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Alcohol and Nicotine Use and Dependence
Stratified by FAAH Genotype
We then assessed the association between the FAAH þ385
genotype and trying nicotine or alcohol. Only 30 people had not
tried nicotine and only 6 people had not tried alcohol so we
could not assess the impact on trying these drugs. The FAAH
þ385 A/A genotype was neither associated with regular use of
nicotine (71.4% vs. 63.6%, N¼ 460, P¼ 0.35) or alcohol (85.7%
vs. 84.3, N¼ 627, P¼ 1.00) nor with nicotine (57.1% vs. 51.6%,
N¼ 373, P¼ 0.52) or with alcohol (25.7% vs. 26.4%, N¼ 196,
P¼ 0.93) dependence among those who had tried them. As the
FAAH genotype was not associated with trying, regular use or
dependence on nicotine or alcohol, these measures were not
assessed in a logistic regression analysis.
Sedative Use and Dependence Stratified
by FAAH Genotype
Since regular sedative use was found to be associated with
the FAAH þ385 A/A genotype (Table IA), this finding
was examined further. Among the total sample, the FAAH þ
385 A/A genotype subjects those with the C/A or C/C genotypes
showed a non-significant trend towards higher trying of
sedatives (54.3% vs. 42.9%,N¼ 325,P¼ 0.18) and a significant
increase in the risk for regular sedative use (57.9% vs. 34.7%,
N¼ 116, P¼ 0.04). In addition the A/A genotype, among those
who tried sedatives (N¼ 325) had modestly higher risk for
dependence, (21.1%vs. 11.4%,N¼ 39,P¼ 0.26), whichwas not
significant. This preliminary association of the FAAHþ385 A/
A genotype with sedative use will need to be retested
prospectively on a larger sample size to confirm these
observations.
Regular Drug Use Stratified by Trying
THC and THC Dependence
Table II contains the frequency distributions for regular
drug use stratified by THC use. In contrast with the genotype
results inTable I, thereweredifferences between thosewhodid
and did not report trying THC in terms of regular drug use. In
the full sample (Table IIA), those who tried THC were more
likely to report regular use of all six other drug classes.
TABLE I. Association of Drug Use and FAAHGenotype, Within the Total Sample (A) andWithin the Subgroup who had Tried THC (B)
(A) Total study sample N¼749 (B) Among those who tried THC N¼489
C/A and C/C
N¼ 714 (%) A/A N¼35 (%) P-value
C/A and C/C
N¼ 462 (%) A/A N¼27 (%) P-value
Tried THC 462 (64.7) 27 (77.1) 0.18 — — —
Not tried THC 252 (35.3) 8 (22.9)
THC dependent — — — 124 (26.8) 3 (11.1) 0.049a
Not dependent 338 (73.2) 24 (88.9)
Alcohol regular user 597 (83.6) 30 (85.7) 0.48a 426 (92.2) 24 (88.9) 0.21a
Not regular user 117 (16.4) 5 (14.3) 36 (7.8) 3 (11.1)
Hallucinogen regular user 122 (17.1) 6 (17.1) 0.99 121 (26.2) 6 (22.2) 0.65
Not regular user 592 (82.9) 29 (82.9) 341 (73.8) 21 (77.8)
Nicotine regular user 435 (60.9) 25 (71.4) 0.21 357 (77.3) 24 (88.9) 0.12a
Not regular user 279 (39.1) 10 (28.6) 105 (22.7) 3 (11.1)
Opiate regular user 106 (14.8) 7 (20.0) 0.41 80 (17.3) 6 (22.2) 0.52
Not regular user 608 (85.2) 28 (80.0) 382 (82.7) 21 (77.8)
Sedative regular user 105 (14.7) 11 (31.4) 0.008 78 (16.9) 10 (37.0) 0.008
Not regular user 609 (85.3) 24 (68.6) 384 (83.1) 17 (63.0)
Stimulant regular user 109 (15.3) 5 (14.3) 0.55a 104 (22.5) 5 (18.5) 0.41a
Not regular user 605 (84.7) 30 (85.7) 358 (77.5) 22 (81.5)
aIndicates a Fisher’s exact test.
TABLE II. Association of Trying THC (A) or THC Dependence (B) With Regular Use of Other Drugs
(A) Total study sample and trying
THC, N¼749










Alcohol regular user 177 (68.1) 450 (92.0) <0.0001 328 (90.6) 122 (96.1) 0.033a
Not regular user 83 (31.9) 39 (8.0) 34 (9.4) 5 (3.9)
Hallucinogen regular user 1 (0.4) 127 (26.0) <0.0001a 54 (14.9) 73 (57.5) <0.0001
Not regular user 259 (99.6) 362 (74.0) 308 (85.1) 54 (42.5)
Nicotine regular user 79 (30.4) 381 (77.9) <0.0001 258 (71.3) 123 (96.8) <0.0001a
Not regular user 181 (69.6) 108 (22.1) 104 (28.7) 4 (3.2)
Opiate regular user 27 (10.4) 86 (17.6) 0.009 56 (15.5) 30 (23.6) 0.038
Not regular user 333 (89.6) 403 (82.4) 306(84.5) 97 (76.4)
Sedative regular user 28 (10.8) 88 (18.0) 0.009 59 (16.3) 29 (22.8) 0.099
Not regular user 232 (89.2) 401 (82.0) 303 (83.7) 98 (77.2)
Stimulant regular user 5 (1.9) 109 (22.3) <0.0001a 57 (15.8) 52 (40.9) <0.0001
Not regular user 255 (98.1) 380 (77.7) 305 (84.2) 75 (59.1)
aIndicates a Fisher’s exact test.
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Similarly, among those who tried THC (Table IIB), those who
were THC dependent were much more likely to report regular
drug use of all six other drug classes.
Trying THC and THC Dependence:
A Logistic Regression Model
Given the relationship between FAAH genotype and THC
use, logistic regression analyseswere conducted to seehow this
relationship changed with the addition of regular use of other
drug classes. The results in Table IIIA show that there were
some suggestive trends with the FAAH þ385 A/A genotype
more likely to have tried THC than those with the C/A or C/C
genotypes but this was not statistically significant since the
confidence intervals included 1.
In contrast, Table IIIB indicates that, among thosewho tried
THC, those with the FAAH þ385 A/A genotype seemed less
likely to become dependent on THC than those with the other
genotypes (OR¼ 0.34, 95%CI (0.10, 1.15)) but this alsowas not
significant due to the confidence intervals including 1. Since
both nicotine and sedatives were identified individually as
confounders, they were added simultaneously to the model. In
contrast with the results on trying THC, the combined effect
was to further strengthen the relationship between FAAH and
THC dependence (OR¼ 0.25 95% CI (0.07, 0.88)), indicating
that theFAAHþ385A/Agenotype subjects are at lower risk for
THC dependence, independent of their regular use of either
nicotine or sedatives.
DISCUSSION
The provocative finding that a missense variant (P129T) in
FAAH, the principal enzyme that terminates signaling for
several endocannabinoids including AEA and OEA, was
significantly associated with street drug use and problem drug
use [Sipe et al., 2002] suggested this naturally occurring
genetic variant as a possible risk factor in trying drugs and
drug dependence. However, whether the FAAH þ385 A/A
(P129T) polymorphism is a genetic risk factor for any specific
group of drugs of abuse could not be determined from this
previous study [Sipe et al., 2002]. To investigate this issue, we
studiedhere a large homogeneous cohort of Caucasian subjects
fromTorontowithpatterns ofmultiple druguse includingTHC
DSM IV dependence. The results of this case control study first
indicate (Table I) that in subjects with the FAAH þ385 A/A
genotype there was a suggestion of an increased likelihood of
trying THC but this was not statistically significant. However,
among those who tried THC, the A/A subjects were signifi-
cantly less likely to become THC dependent. Although this
finding needs to be confirmed in an independent study, it
suggests that the FAAH þ385 A/A genotype may increase the
risk for trying THC but reduces the vulnerability to THC
dependence. The suggestion of an increased risk of trying THC
is consistentwith the previousfindings that risk for street drug
use was increased in the A/A genotype [Sipe et al., 2002]. In
contrast with trying THC, the A/A genotype was associated
with a reduced risk for THC dependence among those who had
tried THC. Although seemingly contradictory findings, these
effects could be explained by the reduction in FAAH activity in
A/A subjects [Chiang et al., 2004] leading to increased
endogenous anandamide levels that have been shown to
reduce anxiety in mammals [Kathuria et al., 2003; Patel and
Hillard, 2006] and supported by effects of exogenous cannabi-
noids on anxiety [Rutkowska et al., 2006]. Thus, reduced
anxiety as a result of the FAAHP129Tmissensemutationmay
result in increased risk taking, such as trying drugs of abuse,
butmayalso result in reducingTHCcravingandwithdrawal in
A/A individuals usingTHC, resulting in a reduced risk forTHC
dependence. We examined the risk for trying THC and THC
regular use and dependence in A/AþC/A compared to the C/C
individuals anddidnot observeanyassociations. This supports
the finding that two copies of the FAAH þ385 A allele are
required for the reduced vulnerability to THC dependence in
association with the P129T FAAH decreased activity and
expression [Chiang et al., 2004].Risk, associatedwitha specific
genetic factor, for initiating use of a specific drug is not always
associated with an increased risk for dependence on a drug as
different factors influence the ‘‘risk’’ taking aspects of trying an
illicit drug relative to becoming dependent [Lerman et al.,
2001; Sullivan et al., 2001; Ito et al., 2003; Jin et al., 2005].
In the entire study sample, there was no indication that the
FAAH þ385 A/A genotype subjects had greater regular use of
nicotine or alcohol (Table IA). However, the most striking
finding was the consistent association between FAAH geno-
type and the regular use of sedative drugs (Table I). Given
these apparent drug-specific effects of the FAAH þ385 A/A
genotype, for examplewith sedatives, we performed additional
analyses to ask whether the genotype effects were specific for
certain drug classes or were part of an overall increased drug
use effect for multiple drugs. These analyses showed that the
effect was confined only to sedatives and nicotine and was not
part of a general drug reward and craving response. The lack of
association of FAAH þ385 A/A genotype with an overall
increased drug use is also consistent with data showing that it
TABLE III. Odds for FAAH Genotype (A/A vs. C/AþC/C) in Relation to Trying THC (A) and THC Dependence (B), Controlling for
Regular Use of Other Drugs (Odds Ratios and 95% Confidence Intervals)
Risk factors:
Odds ratios (95% confidence intervals)
(A) Total sample
(N¼749): tried THC vs. not
(B) Among those who had tried THC
(N¼ 489): THC dependence vs. not
FAAH A/A genotype 1.84 (0.82, 4.11) 0.34 (0.10, 1.15)
Effect of FAAH A/A genotype controlling for
Alcohol regular use 1.88 (0.81, 4.36) 0.35 (0.10, 1.18)
Hallucinogen regular use 1.94 (0.85, 4.45) 0.31 (0.09, 1.15)
Nicotine regular use 1.63 (0.67, 3.96) 0.28 (0.08, 0.95)
Opiate regular use 1.80 (0.80, 4.03) 0.33 (0.10, 1.11)
Sedative regular use 1.69 (0.75, 3.81) 0.30 (0.09, 1.04)
Stimulant regular use 1.94 (0.85, 4.40) 0.34 (0.10, 1.18)
Final logistic regression model
Nicotine and sedative regular use 1.53 (0.62, 3.76) 0.25 (0.07, 0.88)
Identified as confounders.
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did not alter the risk for methamphetamine dependence
[Morita et al., 2005]. When we assessed the risk of the FAAH
þ385 A/A genotype alone for regular use of nicotine and
alcohol, there was clearly no association, confirming a similar
result in our previous report in white subjects [Sipe et al.,
2002].
These data also suggested some association of FAAH þ385
genotype with sedative use. While the molecular mechanism
for the association of sedative use and abuse with the FAAH
þ385 genotype is unknown, the role of sedatives in reducing
anxiety and panic could be potentiated in subjects with this
genotype who may have increased ANA levels [Patel and
Hillard, 2006;Rutkowska et al., 2006] and could lead to regular
sedative abuse. As sedatives are widely used and abused, this
novel and potentially clinically relevant observation should be
prospectively tested in populations of both sedative users that
are under the direction of physicians and those who use
sedatives recreationally.
In this study,wehave shownpreliminary evidence of several
drug-specific risk factors associated with the FAAH þ385 A/A
missense polymorphism. We found that the A/A genotype was
associated with reduced vulnerability to THC dependence and
this reduced risk was enhanced by the regular use of sedatives
and nicotine. Reduced vulnerability appeared to be specific for
THC dependence and was not associated with risk for general
druguse.Wealso confirmedearlierfindings that thosewith the
FAAH A/A genotype were not at greater risk for use of alcohol
or nicotine and further clarified that risk for dependence on
these drugs was also not altered. However, a very strong and
consistent association between FAAH genotype and risk for
regular use of sedatives was found (with or without THC use)
and this should be examined further in populations at risk
for clinical and non-clinical sedative drug use. Due to the
exploratory hypothesis-generating nature of this study, con-
firmation of these results should be obtained by prospective
testing in larger populations of differing ethnic composition. In
this way, it may be possible to identify specific genetic
vulnerability traits for populations at risk for THC drug abuse
and dependence and other drugs of abuse.
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